why choose us

First received: April 04, 2023

Clinical Trial: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hereditary Angioedema (HAE)

Study Type: INTERVENTIONAL


Official Title: A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects

Brief Summary: The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Read more